QuantalX Named Finalist in the 2026 Digital Health & AI Awards
NEW YORK — October 21, 2026 — QuantalX™ Neuroscience, the company translating brain signals into better care, today announced that it has been named a finalist in the 2026 Digital Health & AI Awards in the Rising Star – Brain Health category. The Digital Health & AI Awards recognize innovations shaping the future of healthcare.
Neurologists can assess symptoms, review imaging and identify biomarkers, but they have lacked a standardized way to directly measure how brain networks are functioning. That gap can delay diagnosis and intervention. QuantalX was recognized for addressing this gap with Delphi-MD™, the first FDA De Novo-cleared system.
Iftach Dolev, QuantalX CEO and Co-Founder, said: “QuantalX is honored to be recognized by the Digital Health Hub Foundation for our work redefining brain healthcare with our Delphi-MD. Real-time insights on brain network function enable clinicians to make earlier, more precise treatment decisions with the goal of driving better outcomes for patients.”
Delphi-MD stimulates targeted brain networks, records their responses and compares them to an age-matched normative database to quantify reactivity, excitability, and connectivity. The 30-40 minute test is non-invasive and radiation-free, and requires no active participation. It adds an objective functional layer to clinical evaluation of brain disorders such as cognitive decline, neurodegeneration, traumatic brain injury and stroke.
"The transition from Quarterfinalist to Finalist is where the competition really gets exciting," said Mark H. Goldstein, Chairman of the Digital Health Hub Foundation. "We're seeing companies move beyond promising ideas to solutions that are changing how healthcare is delivered, experienced, and accessed. Our finalists represent an extraordinary range of innovation, and we can't wait to bring their achievements to the stage at HLTH in November.”
About QuantalX™ Neuroscience
QuantalX™ Neuroscience is on a mission to help clinicians diagnose brain disorders earlier and more easily, revolutionize the assessment of brain health, and bring direct functional brain diagnostics to the point of care. With its Delphi‑MD™ path-breaking, first-of-its-kind, FDA-cleared system, QuantalX™ provides neurologists, neurosurgeons, and psychiatrists new access to the inner workings of the brain so they can make better-informed decisions about planning care for their patients. After years of use in groundbreaking research trials at institutions like UCSF, Mass General, and Penn, Delphi‑MD™ has received FDA De Novo clearance. Looking ahead, Delphi‑MD™ aims to enable continuous, real-world data generation on brain function over time, creating a proprietary dataset that can fuel intelligence-driven advancements in precision brain healthcare. Visit QuantalX.com to learn more about the commercially available device and follow us on LinkedIn.
Media Contact
helen@quantalx.com